Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)

Detalhes bibliográficos
Autor(a) principal: Barros, Grasiela Costa Bezerra
Data de Publicação: 2021
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da UFPB
Texto Completo: https://repositorio.ufpb.br/jspui/handle/123456789/20742
Resumo: 4-carvomenthenol (Carvo) or terpinene-4-ol is a monoterpene present in essential oils from pharmacologically active aromatic plants. Therapeutic activities include anti-inflammatory and immunomodulatory properties. Asthma and allergic rhinitis are chronic airway diseases that coexist with high global prevalence, generating negative economic and social impacts. To control both diseases, the drug combination is used unsuccessfully in several patients, in addition to generating serious side effects. This study aimed to analyze oral treatment with Carvo in the experimental model of Combined Asthma and Allergic Rhinitis Syndrome (CARAS). BALB/c mice were sensitized with ovalbumin (OVA) on day zero and seventh (50 μg / mL OVA in 10 mg/mL Al (OH) 3) and challenged by OVA (5 mg / mL, 20 μL / animal) for three weeks. In the last week, the animals were challenged with an OVA aerosol and the treatment with Carvo (12.5, 25, or 50 mg/kg) occurred one hour before each OVA challenge. Data were analyzed and p <0.05 was considered significant. Carvo (12.5-50 mg/kg) decreased the migration of eosinophils in the upper (NALF) and lower (BALF) airways, as well as in the nasal and lung tissues of sick animals. The treatment also decreased mucus production in both tissue sections stained with PAS (periodic acid-Schiff). Histological analyzes showed that sick mice showed hyperplasia and hypertrophy of the smooth muscle layer of the lung, followed by an increase in the extracellular matrix, however, Carvo (50 mg/kg) inhibited these asthmatic parameters. The signs of allergic rhinitis, such as nasal rubs and sneezing, were analyzed and it was observed that the Carvo decreased these two nasal signs, as well as the specific IgE-OVA titer, and the cytokine IL-13, with an increase in IL-10. The decrease in IL-13 production corroborated with the decrease in mucus production and these effects were dependent on the inhibition of the p38MAPK / NF-κB signaling pathway (p65). Therefore, these data demonstrated that 4- Carvomenthenol has antiallergic properties in an experimental model of CARAS, suggesting a new drug prototype for the treatment of this allergic syndrome.
id UFPB_db87b4b038deed8492ee4dc99adad5a5
oai_identifier_str oai:repositorio.ufpb.br:123456789/20742
network_acronym_str UFPB
network_name_str Biblioteca Digital de Teses e Dissertações da UFPB
repository_id_str
spelling Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)4-CarvomenthenolÓleo essencialRiniteAsmaAlergiaImunomodulaçãoEssential oilRhinitisAsthmaAllergyImmunomodulationCNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA4-carvomenthenol (Carvo) or terpinene-4-ol is a monoterpene present in essential oils from pharmacologically active aromatic plants. Therapeutic activities include anti-inflammatory and immunomodulatory properties. Asthma and allergic rhinitis are chronic airway diseases that coexist with high global prevalence, generating negative economic and social impacts. To control both diseases, the drug combination is used unsuccessfully in several patients, in addition to generating serious side effects. This study aimed to analyze oral treatment with Carvo in the experimental model of Combined Asthma and Allergic Rhinitis Syndrome (CARAS). BALB/c mice were sensitized with ovalbumin (OVA) on day zero and seventh (50 μg / mL OVA in 10 mg/mL Al (OH) 3) and challenged by OVA (5 mg / mL, 20 μL / animal) for three weeks. In the last week, the animals were challenged with an OVA aerosol and the treatment with Carvo (12.5, 25, or 50 mg/kg) occurred one hour before each OVA challenge. Data were analyzed and p <0.05 was considered significant. Carvo (12.5-50 mg/kg) decreased the migration of eosinophils in the upper (NALF) and lower (BALF) airways, as well as in the nasal and lung tissues of sick animals. The treatment also decreased mucus production in both tissue sections stained with PAS (periodic acid-Schiff). Histological analyzes showed that sick mice showed hyperplasia and hypertrophy of the smooth muscle layer of the lung, followed by an increase in the extracellular matrix, however, Carvo (50 mg/kg) inhibited these asthmatic parameters. The signs of allergic rhinitis, such as nasal rubs and sneezing, were analyzed and it was observed that the Carvo decreased these two nasal signs, as well as the specific IgE-OVA titer, and the cytokine IL-13, with an increase in IL-10. The decrease in IL-13 production corroborated with the decrease in mucus production and these effects were dependent on the inhibition of the p38MAPK / NF-κB signaling pathway (p65). Therefore, these data demonstrated that 4- Carvomenthenol has antiallergic properties in an experimental model of CARAS, suggesting a new drug prototype for the treatment of this allergic syndrome.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESO 4-carvomenthenol (Carvo) ou terpinen-4-ol é um monoterpeno presente em óleos essenciais de plantas aromáticas farmacologicamente ativas. Entre as atividades terapêuticas estão propriedades anti-inflamatórias e imunomoduladoras. Asma e rinite alérgica são doenças crônicas das vias aéreas que coexistem com alta prevalência global, gerando impactos econômicos e sociais negativos. Para controlar ambas as doenças, a associação medicamentosa é utilizada sem sucesso em um certo número de pacientes, além de gerar efeitos colaterais graves. O objetivo deste estudo foi analisar o tratamento oral com o Carvo no modelo experimental da Síndrome de Asma e Rinite Alérgica Combinadas (CARAS). Os camundongos BALB/c foram sensibilizados com ovalbumina (OVA) no dia zero e sétimo (50 μg/mL de OVA em 10 mg/mL de Al (OH)3) e desafiados por OVA (5 mg/mL, 20 μL/animal) por três semanas. Na última semana, os animais foram desafiados com um aerossol de OVA e o tratamento com Carvo (12,5, 25 ou 50 mg/kg) ocorreu uma hora antes de cada desafio de OVA. Os dados foram analisados e p <0,05 foi considerado significativo. O Carvo (12,5-50 mg/kg) diminuiu a migração de eosinófilos nas vias aéreas superiores (NALF) e inferiores (BALF), bem como nos tecidos nasais e pulmonares de animais doentes. O tratamento também diminuiu a produção de muco em ambas as seções de tecido coradas com PAS (ácido periódico-Schiff). As análises histológicas demonstraram que camundongos doentes apresentaram hiperplasia e hipertrofia da camada de músculo liso do pulmão, seguidos pelo aumento da matriz extracelular, no entanto, o Carvo (50 mg/kg) inibiu esses parâmetros asmáticos. Os sinais de rinite alérgica como fricções nasais e espirros foram analisados e observou-se que o Carvo diminuiu esses dois sinais nasais, bem como o título sérico de IgE- OVA específica, e a citocina IL-13, com aumento de IL-10. A diminuição da produção de IL-13 corroborou com a diminuição da produção de muco e esses efeitos foram dependentes da inibição da via de sinalização de p38MAPK/NF-κB (p65). Portanto, esses dados demonstraram que o 4-Carvomenthenol apresenta propriedade antialérgica em um modelo experimental de CARAS, sugerindo um novo protótipo de medicamento para o tratamento dessa síndrome alérgica.Universidade Federal da ParaíbaBrasilFarmacologiaPrograma de Pós-Graduação em Produtos Naturais e Sintéticos BioativosUFPBPiuvezam, Marcia Reginahttp://lattes.cnpq.br/0961955935523938Barros, Grasiela Costa Bezerra2021-08-16T15:07:56Z2021-04-072021-08-16T15:07:56Z2021-02-24info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttps://repositorio.ufpb.br/jspui/handle/123456789/20742porhttp://creativecommons.org/licenses/by-nd/3.0/br/info:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFPBinstname:Universidade Federal da Paraíba (UFPB)instacron:UFPB2022-08-10T10:49:39Zoai:repositorio.ufpb.br:123456789/20742Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufpb.br/PUBhttp://tede.biblioteca.ufpb.br:8080/oai/requestdiretoria@ufpb.br|| diretoria@ufpb.bropendoar:2022-08-10T10:49:39Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB)false
dc.title.none.fl_str_mv Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)
title Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)
spellingShingle Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)
Barros, Grasiela Costa Bezerra
4-Carvomenthenol
Óleo essencial
Rinite
Asma
Alergia
Imunomodulação
Essential oil
Rhinitis
Asthma
Allergy
Immunomodulation
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
title_short Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)
title_full Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)
title_fullStr Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)
title_full_unstemmed Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)
title_sort Efeito do tratamento com o monoterpeno sintético 4-carvomenthenol em modelo experimental da síndrome da asma e rinite alérgicas combinadas (CARAS)
author Barros, Grasiela Costa Bezerra
author_facet Barros, Grasiela Costa Bezerra
author_role author
dc.contributor.none.fl_str_mv Piuvezam, Marcia Regina
http://lattes.cnpq.br/0961955935523938
dc.contributor.author.fl_str_mv Barros, Grasiela Costa Bezerra
dc.subject.por.fl_str_mv 4-Carvomenthenol
Óleo essencial
Rinite
Asma
Alergia
Imunomodulação
Essential oil
Rhinitis
Asthma
Allergy
Immunomodulation
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
topic 4-Carvomenthenol
Óleo essencial
Rinite
Asma
Alergia
Imunomodulação
Essential oil
Rhinitis
Asthma
Allergy
Immunomodulation
CNPQ::CIENCIAS BIOLOGICAS::FARMACOLOGIA
description 4-carvomenthenol (Carvo) or terpinene-4-ol is a monoterpene present in essential oils from pharmacologically active aromatic plants. Therapeutic activities include anti-inflammatory and immunomodulatory properties. Asthma and allergic rhinitis are chronic airway diseases that coexist with high global prevalence, generating negative economic and social impacts. To control both diseases, the drug combination is used unsuccessfully in several patients, in addition to generating serious side effects. This study aimed to analyze oral treatment with Carvo in the experimental model of Combined Asthma and Allergic Rhinitis Syndrome (CARAS). BALB/c mice were sensitized with ovalbumin (OVA) on day zero and seventh (50 μg / mL OVA in 10 mg/mL Al (OH) 3) and challenged by OVA (5 mg / mL, 20 μL / animal) for three weeks. In the last week, the animals were challenged with an OVA aerosol and the treatment with Carvo (12.5, 25, or 50 mg/kg) occurred one hour before each OVA challenge. Data were analyzed and p <0.05 was considered significant. Carvo (12.5-50 mg/kg) decreased the migration of eosinophils in the upper (NALF) and lower (BALF) airways, as well as in the nasal and lung tissues of sick animals. The treatment also decreased mucus production in both tissue sections stained with PAS (periodic acid-Schiff). Histological analyzes showed that sick mice showed hyperplasia and hypertrophy of the smooth muscle layer of the lung, followed by an increase in the extracellular matrix, however, Carvo (50 mg/kg) inhibited these asthmatic parameters. The signs of allergic rhinitis, such as nasal rubs and sneezing, were analyzed and it was observed that the Carvo decreased these two nasal signs, as well as the specific IgE-OVA titer, and the cytokine IL-13, with an increase in IL-10. The decrease in IL-13 production corroborated with the decrease in mucus production and these effects were dependent on the inhibition of the p38MAPK / NF-κB signaling pathway (p65). Therefore, these data demonstrated that 4- Carvomenthenol has antiallergic properties in an experimental model of CARAS, suggesting a new drug prototype for the treatment of this allergic syndrome.
publishDate 2021
dc.date.none.fl_str_mv 2021-08-16T15:07:56Z
2021-04-07
2021-08-16T15:07:56Z
2021-02-24
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.ufpb.br/jspui/handle/123456789/20742
url https://repositorio.ufpb.br/jspui/handle/123456789/20742
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv http://creativecommons.org/licenses/by-nd/3.0/br/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nd/3.0/br/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade Federal da Paraíba
Brasil
Farmacologia
Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos
UFPB
publisher.none.fl_str_mv Universidade Federal da Paraíba
Brasil
Farmacologia
Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos
UFPB
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFPB
instname:Universidade Federal da Paraíba (UFPB)
instacron:UFPB
instname_str Universidade Federal da Paraíba (UFPB)
instacron_str UFPB
institution UFPB
reponame_str Biblioteca Digital de Teses e Dissertações da UFPB
collection Biblioteca Digital de Teses e Dissertações da UFPB
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB)
repository.mail.fl_str_mv diretoria@ufpb.br|| diretoria@ufpb.br
_version_ 1801842979000811520